Konrad M, Rinscheid A, Wienand G, Nittbaur B, Wester H, Janzen T
Eur J Nucl Med Mol Imaging. 2023; 50(13):3937-3948.
PMID: 37597009
PMC: 10611619.
DOI: 10.1007/s00259-023-06395-x.
Varasteh Z, Weber W, Rischpler C
Pharmaceuticals (Basel). 2022; 15(2).
PMID: 35215296
PMC: 8875369.
DOI: 10.3390/ph15020183.
Raynor W, Park P, Borja A, Sun Y, Werner T, Ng S
Diagnostics (Basel). 2021; 11(12).
PMID: 34943473
PMC: 8700072.
DOI: 10.3390/diagnostics11122234.
Schottelius M, Herrmann K, Lapa C
Cancers (Basel). 2021; 13(23).
PMID: 34885030
PMC: 8656854.
DOI: 10.3390/cancers13235920.
Corovic A, Nus M, Mallat Z, Rudd J, Tarkin J
Curr Cardiol Rep. 2021; 23(8):99.
PMID: 34196824
PMC: 8249287.
DOI: 10.1007/s11886-021-01529-9.
Molecular Imaging Using Cardiac PET/CT: Opportunities to Harmonize Diagnosis and Therapy.
Thackeray J
Curr Cardiol Rep. 2021; 23(8):96.
PMID: 34196821
PMC: 8249297.
DOI: 10.1007/s11886-021-01526-y.
Emerging methods for the characterization of ischemic heart disease: ultrafast Doppler angiography, micro-CT, photon-counting CT, novel MRI and PET techniques, and artificial intelligence.
Willemink M, Varga-Szemes A, Schoepf U, Codari M, Nieman K, Fleischmann D
Eur Radiol Exp. 2021; 5(1):12.
PMID: 33763754
PMC: 7991013.
DOI: 10.1186/s41747-021-00207-3.
Imaging Inflammation with Positron Emission Tomography.
Iking J, Staniszewska M, Kessler L, Klose J, Luckerath K, Fendler W
Biomedicines. 2021; 9(2).
PMID: 33669804
PMC: 7922638.
DOI: 10.3390/biomedicines9020212.
Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review.
Windisch P, Zwahlen D, Giesel F, Scholz E, Lugenbiel P, Debus J
EJNMMI Res. 2021; 11(1):18.
PMID: 33606104
PMC: 7895887.
DOI: 10.1186/s13550-021-00761-2.
A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
Osl T, Schmidt A, Schwaiger M, Schottelius M, Wester H
Theranostics. 2020; 10(18):8264-8280.
PMID: 32724470
PMC: 7381729.
DOI: 10.7150/thno.45537.
PET imaging of macrophages in cardiovascular diseases.
Li X, Rosenkrans Z, Wang J, Cai W
Am J Transl Res. 2020; 12(5):1491-1514.
PMID: 32509158
PMC: 7270023.
CXCR4-Directed Imaging in Solid Tumors.
Werner R, Kircher S, Higuchi T, Kircher M, Schirbel A, Wester H
Front Oncol. 2019; 9:770.
PMID: 31475113
PMC: 6702266.
DOI: 10.3389/fonc.2019.00770.
Molecular Imaging in Ischemic Heart Disease.
Lavin Plaza B, Theodoulou I, Rashid I, Hajhosseiny R, Phinikaridou A, Botnar R
Curr Cardiovasc Imaging Rep. 2019; 12(7):31.
PMID: 31281564
PMC: 6557873.
DOI: 10.1007/s12410-019-9500-x.
Molecular Imaging Visualizes Recruitment of Inflammatory Monocytes and Macrophages to the Injured Heart.
Heo G, Kopecky B, Sultan D, Ou M, Feng G, Bajpai G
Circ Res. 2019; 124(6):881-890.
PMID: 30661445
PMC: 6435034.
DOI: 10.1161/CIRCRESAHA.118.314030.
CXCR4-directed theranostics in oncology and inflammation.
Kircher M, Herhaus P, Schottelius M, Buck A, Werner R, Wester H
Ann Nucl Med. 2018; 32(8):503-511.
PMID: 30105558
PMC: 6182637.
DOI: 10.1007/s12149-018-1290-8.
First F-Labeled Pentixafor-Based Imaging Agent for PET Imaging of CXCR4 Expression In Vivo.
Poschenrieder A, Osl T, Schottelius M, Hoffmann F, Wirtz M, Schwaiger M
Tomography. 2018; 2(2):85-93.
PMID: 30042959
PMC: 6024415.
DOI: 10.18383/j.tom.2016.00130.
Prospective of Ga Radionuclide Contribution to the Development of Imaging Agents for Infection and Inflammation.
Velikyan I
Contrast Media Mol Imaging. 2018; 2018:9713691.
PMID: 29531507
PMC: 5817300.
DOI: 10.1155/2018/9713691.
PET Assessment of Immune Cell Activity and Therapeutic Monitoring Following Myocardial Infarction.
Thackeray J
Curr Cardiol Rep. 2018; 20(3):13.
PMID: 29511843
DOI: 10.1007/s11886-018-0955-1.
Targeting CXCR4 with [Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?.
Lapa C, Kircher S, Schirbel A, Rosenwald A, Kropf S, Pelzer T
Oncotarget. 2017; 8(57):96732-96737.
PMID: 29228566
PMC: 5722518.
DOI: 10.18632/oncotarget.18235.
[68Ga]Pentixafor-PET/MRI for the detection of Chemokine receptor 4 expression in atherosclerotic plaques.
Li X, Heber D, Leike T, Beitzke D, Lu X, Zhang X
Eur J Nucl Med Mol Imaging. 2017; 45(4):558-566.
PMID: 28932900
PMC: 5829117.
DOI: 10.1007/s00259-017-3831-0.
